| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,750,000 |
| Market
Cap: |
184.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.77 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.5 |
| Insider 6 Months : 12.5 |
| Insider 3/6 Months : 25.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
68,600 |
68,600 |
96,450 |
225,574 |
| Total Buy Value |
$872,910 |
$872,910 |
$1,130,787 |
$2,406,697 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
8 |
8 |
23 |
59 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Snehal |
CEO and CFO |
• • • |
2022-06-24 |
4 |
B |
$9.13 |
$59,025 |
I/I |
6,465 |
2,712,886 |
2.64 |
9% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-24 |
4 |
B |
$9.13 |
$205,745 |
D/D |
22,535 |
2,706,421 |
3.23 |
9% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-16 |
4 |
B |
$7.13 |
$57,040 |
D/D |
8,000 |
2,683,886 |
3.23 |
38% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-14 |
4 |
B |
$7.91 |
$94,920 |
D/D |
12,000 |
2,675,886 |
3.23 |
20% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-10 |
4 |
B |
$8.33 |
$99,960 |
D/D |
12,000 |
2,663,886 |
3.23 |
17% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-09 |
4 |
B |
$10.90 |
$49,050 |
D/D |
4,500 |
1,243,453 |
3.23 |
-9% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-07 |
4 |
B |
$8.55 |
$51,300 |
D/D |
6,000 |
1,238,953 |
3.23 |
15% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-03 |
4 |
B |
$8.35 |
$77,238 |
D/D |
9,250 |
1,232,953 |
3.23 |
9% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-06-02 |
4 |
B |
$7.38 |
$49,992 |
D/D |
6,774 |
1,223,703 |
3.23 |
20% |
|
| Daugherty Frank Joseph |
Chief Medical Officer |
• • – |
2022-04-25 |
4 |
B |
$16.25 |
$16,250 |
D/D |
1,000 |
90,121 |
2.81 |
-45% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-04-21 |
4 |
B |
$16.09 |
$96,540 |
D/D |
6,000 |
1,216,929 |
3.23 |
-40% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-04-19 |
4 |
B |
$16.74 |
$100,440 |
D/D |
6,000 |
1,210,929 |
3.23 |
-45% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2022-04-19 |
4 |
B |
$16.74 |
$8,370 |
D/D |
500 |
255,995 |
2.74 |
-45% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-02-11 |
4 |
B |
$19.80 |
$108,900 |
D/D |
5,500 |
1,204,929 |
3.23 |
-58% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-02-04 |
4 |
B |
$19.59 |
$97,950 |
D/D |
5,000 |
1,199,429 |
3.23 |
-59% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2022-01-31 |
4 |
B |
$18.47 |
$9,235 |
D/D |
500 |
255,495 |
2.74 |
-43% |
|
| Hallock Kenneth |
Director |
– • – |
2022-01-21 |
4 |
B |
$16.32 |
$4,896 |
D/D |
300 |
397,304 |
2.31 |
-55% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2022-01-21 |
4 |
B |
$16.33 |
$8,165 |
D/D |
500 |
254,995 |
2.74 |
-55% |
|
| Thompson Jaye |
VP Clinical Reg. Affairs |
• – – |
2022-01-18 |
4 |
B |
$18.87 |
$9,435 |
D/D |
500 |
254,495 |
2.74 |
-58% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-01-13 |
4 |
B |
$19.99 |
$19,990 |
D/D |
1,000 |
1,194,429 |
3.15 |
-58% |
|
| Thompson Jaye |
VP Clinical Reg. Affairs |
• – – |
2022-01-13 |
4 |
B |
$19.99 |
$19,990 |
D/D |
1,000 |
253,995 |
2.74 |
-58% |
|
| Daugherty Frank Joseph |
Chief Medical Officer |
• • – |
2022-01-13 |
4 |
B |
$19.99 |
$19,990 |
D/D |
1,000 |
89,121 |
2.81 |
-58% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2022-01-03 |
4 |
B |
$23.82 |
$48,831 |
D/D |
2,050 |
1,193,429 |
3.23 |
-59% |
|
| Thompson Jaye |
VP Clinical & Reg. AffairsOffi |
• – – |
2021-12-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
252,995 |
|
-60% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2021-12-14 |
4 |
B |
$27.17 |
$49,992 |
D/D |
1,840 |
1,191,379 |
3.23 |
-46% |
|
106 Records found
|
|
Page 3 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.30 (2.03%) 
